FREE Daily Stock Alerts From Stock-PR.com
Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
ORFG is please to announce that the Board Of Directors have appointed Mr. Ning Shi Long as Chairman of the Board and Executive Director.
Mr. Ary Fernando Pernett Marque has been appointed as the new President/CEO & Executive Director of Orofino Gold Corp. See full resume on ORFG's website.
Mr. Pernett will be responsible for all affairs of ORFG in Colombia. Mr. Pernett has 30 years of experience working in the Colombian Mining sector and will over the near term choose his new development team to assist in the development of the company’s Senderos de Oro gold camp in the Sur de Bolivar Colombia.
ORFG and Mr. Pernett will continue to work with Contexto Legal of Medellin and Bogota, ORFG ’s legal counsel as well as Discovery Consultants, (The Qualified 43-101 team) Canada, as they have in the past. The new team will now aggressively pursue other known Gold occurrences in the companies Senderos de Oro Gold Camp while the development team works to improve production at La Azul Mine.
The Board of Director’s have accepted resignation of John T. Martin, former Managing Director of the Company. His resignation is effective immediately. ORFG wish him well and success in future endeavors.
Enzo Biochem (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community. Founded in 1976, Enzo Biochem has concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of Enzo Biochem’s technologies are applicable to the biomedical and pharmaceutical research markets, and the Company is further using these technologies as a platform for entry into the clinical diagnostics market. Today, Enzo technologies and products are recognized as the key tools in non-radioactive gene labeling used by researchers worldwide. Additionally, Enzo’s work in gene analysis has led to development of a number of significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials. In the course of Enzo Biochem’s extensive research and development activities, they have built a significant patent position consisting of numerous pioneer patents and applications that encompass core technologies.
Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.
“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”
“Moreover, in the first quarter, we achieved several milestones. We submitted Colon Sentry, a unique assay for risk-stratification of colon cancer occurrence, to the New York State Department of Health for approval. In addition, we began enrolling the first patients in our clinical trial of Optiquel™, our candidate therapeutic for the treatment of autoimmune uveitis. We also continued to roll out proprietary products and systems designed to aid in drug development,” he added.
Enzo Clinical Labs (”Lab”) benefited in the quarter from increased market share and service volume increases in connection with its being named a participating provider for Empire BlueCross BlueShield in the metropolitan New York area.
Enzo Life Sciences’ profitability for the quarter improved due to benefits from the plan instituted in July to integrate functions and rationalize workforce levels.
Curis Inc. (Nasdaq:CRIS) announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase (PI3K) and histone deacetylase (HDAC) as a development candidate from its targeted cancer programs. "We are pleased to announce the addition of CUDC-907 to our growing proprietary portfolio of innovative targeted cancer development programs. We believe that this compound, along with previously selected candidates CUDC-101, our EGFR, Her2 and HDAC inhibitor that is currently in Phase Ib testing, and CUDC-305, an HSP90 inhibitor that we licensed to Debiopharm and is currently in Phase I testing, continue to provide validation of the quality of our science and our efforts for developing innovative next generation targeted cancer therapies against a wide range of cancer types, said Curis President and CEO Dan Passeri. “We expect to initiate IND-enabling studies for CUDC-907 shortly and following a favorable outcome, anticipate that we will file an IND application in late 2011.”
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics.
Majesco Entertainment Co. (Nasdaq:COOL) an innovative provider of video games for the mass market, announced that it has sold more than 500,000 units to retailers nationwide of its Zumba FitnessÂ® interactive video game for Wii™, Kinect for the Xbox 360Â® and PlayStationÂ®Move motion controller. The Zumba FitnessÂ® video game has quickly become one of Majesco's fastest-selling titles, having reached this milestone in less than two months. "We are excited by the sales performance of the Zumba FitnessÂ® video game, and are also encouraged by the continued post-holiday momentum for the title," said Jesse Sutton, Chief Executive Officer, Majesco. "ZumbaÂ® fitness programs are a worldwide phenomenon and growing. We believe people will be playing the Zumba FitnessÂ® video game at home 365 days a year, and as such expect to see continued reorders throughout the year.
Majesco Entertainment Company provides interactive entertainment products primarily in the United States and Europe. It offers video game software and other digital entertainment products.
China Direct Industries, Inc. (Nasdaq:CDII) announced that its wholly owned subsidiary CDII Trading, Inc. has entered into a contract with a privately held China-based trading company to supply iron ore from Bolivia. As previously stated in our Form 8-K filed with the Securities and Exchange Commission on December 22, 2010, CDII Trading has been finalizing several supply contracts and sales agreements for iron ore delivery into China from Mexico and parts of South America with shipments expected to begin in the second quarter of fiscal 2011. CDII Trading has agreed to supply iron ore to its China-based buyer over a 12 month period under an agreement with a Bolivian mineral ore mining and exporting company upon acceptance of purchase orders by the parties and fulfillment of other commercial terms in the agreement including the successful completion of an initial test shipment.
China Direct Industries, Inc. engages in the production and distribution of magnesium, and distributes basic materials in the People Republic of China. The company operates two main segments, Magnesium and Basic Materials.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.